Patents/Inventors

Kayvan Niazi

Culver City, CAUS55 patents

48 Patents

US125953072026
Anti-ctla4 Monoclonal Antibodies and Chimeric Antigen Receptors
Nantbio, Inc.
0 cites
US125800562026
Production and Delivery Tracking and Sample Verification of Patient-specific Therapeutics
Nantcell, Inc.
0 cites
US125459282026
Machine Methods to Determine Neoepitope Payload Toxicity
Nantbio, Inc.
0 cites
US124912012025
Maximizing T-cell Memory and Compositions and Methods Therefor
Nantcell, Inc.
0 cites
US124872412025
Rapid Verification of Virus Particle Production for a Personalized Vaccine
Nantbio, Inc.
0 cites
US124743402025
Validation of Neoepitope Presentation
Nant Holdings IP, LLC
0 cites
US124486382025
Enzyme Based System for Production of Messenger RNA with Increased Transfection Efficiency
Immunitybio, Inc.
0 cites
US124166352025
Live Cell Imaging Systems and Methods to Validate Triggering of Immune Response
Nant Holdings IP, LLC
0 cites
US124126392025
Method of Characterizing a Tumor Based on an Immune Gene Expression Signature in Regulatory T Cell (treg)-enriched Tumor Samples
Nant Holdings IP, LLC
0 cites
US123970192025
Mesenchymal Stem Cell Derived Exosomes and Methods
Nantbio, Inc.
0 cites
US123859032025
RP182 Compositions and Methods
Nantbio, Inc.
0 cites
US123503232025
Cellular Adjuvants for Viral Infection
Nantbio, Inc.
0 cites
US123298092025
Cellular Adjuvants for Viral Infection
Nantbio, Inc.
0 cites
US123110182025
Targeted Neoepitope Vectors and Methods Therefor
Nantcell, Inc.
0 cites
US123034772025
HIV Treatment Compositions and Methods
Nantkwest, Inc.
0 cites
US123080952025
Prediction of Computational Pathway Circuits
Nantbio, Inc.
0 cites
US122905582025
Sars-cov-2 Vaccines Comprising Human Adenovirus Vectors Encoding Spike and Nucleocapsid-etsd Immunogens
Immunitybio, Inc.
0 cites
US122854812025
Methods for the Treatment of COVID-19 Comprising Administering Replication-defective Adenoviruses Encoding the Sars-cov-2 Spike Glycoprotein and Modified Nucleocapsid Protein
Nantcell, Inc.
0 cites
US122800922025
Reprogrammed T Cell-like NK Cells
Nantbio, Inc.
0 cites
US122631892025
Mesenchymal Stem Cell Derived Exosomes and Methods
Nantbio, Inc.
0 cites
US122470862025
Enhanced Immunogenicity for Gpi-anchored Antigens
Nantbio, Inc.
0 cites
US122204522025
Cellular Adjuvants for Viral Infection
Nantbio, Inc.
0 cites
US121128382024
Production and Delivery Tracking and Sample Verification of Patient-specific Therapeutics
Nantcell, Inc.
0 cites
US120981772024
Targeted IL-12 Treatments and Methods to Stimulate Hank and Nk92mi Cells
Nantbio, Inc.
0 cites
US120982012024
Anti-tim3 Monoclonal Antibodies and Chimeric Antigen Receptors
Nantbio, Inc.
0 cites
US120945742024
Difference-based Genomic Identity Scores
Nantomics, LLC
0 cites
US120723372024
Circulating Tumor Cell Enrichment Using Neoepitopes
Nant Holdings IP, LLC
0 cites
US120606552024
Mrna Display Antibody Library and Methods
Nantbio, Inc.
0 cites
US120535122024
Method of Validating the Triggering of an Immune Response to a Neoepitope of a Tumor with T-cells
Nantomics, LLC
0 cites
US120168832024
Primary T-cell Expansion
Nantbio, Inc.
0 cites
US120190672024
Interferometry Based Systems to Detect Small Mass Changes of an Object in a Solution
Nantbio, Inc.
0 cites
US119395852024
Multi-pulse Transfection Methods and Cells
Nantbio, Inc.
0 cites
US118941092024
Production and Delivery Tracking and Sample Verification of Patient-specific Therapeutics
Nantcell, Inc.
0 cites
US118576202024
Method of Inducing Immunity Against Sars-cov-2 Using Spike (s) and Nucleocapsid (N)-ETSD Immunogens Delivered by a Replication-defective Adenovirus
Immunitybio, Inc.
0 cites
US118144362023
0 cites
US117865772023
HIV Treatment Compositions and Methods
Nantcell, Inc.
0 cites
US117796372023
Targeted Neoepitope Vectors and Methods Therefor
Nantcell, Inc.
0 cites
US117731582023
Method of Treatment of a Tumor with an IL-8 Antibody
Nantbio, Inc.
0 cites
US117731872023
Enhanced Immunogenicity for Gpi-anchored Antigens
Nantbio, Inc.
0 cites
US117534672023
Anti-tim3 Monoclonal Antibodies and Chimeric Antigen Receptors
Nantbio, Inc.
0 cites
US117566512023
Method of Treating a Tumor in a Patient Based on an Immune Gene Expression
Nant Holdings IP, LLC
0 cites
US117251862023
Recombinant NK Cells Expressing Co-stimulatory Molecules
Nant Holdings IP, LLC
0 cites
US117175642023
Iterative Discovery of Neoepitopes and Adaptive Immunotherapy and Methods Therefor
Nantomics, LLC
0 cites
US116846682023
Replication-defective Adenoviruses Comprising Nucleic Acids Encoding Sars-cov-2 S Glycoprotein and Modified N Protein Comprising an Endosomal Targeting Sequence
Nantcell, Inc.
0 cites
US116230012023
Compositions and Methods for Viral Cancer Neoepitopes
Nantomics, LLC
0 cites
US116261872023
Systems, Compositions, and Methods for Discovery of MSI and Neoepitopes That Predict Sensitivity to Checkpoint Inhibitors
Nantomics LLC
0 cites
US115858052023
Methods of Immunogenic Modulation
Nant Holdings IP, LLC
0 cites
US115732302023
Rapid Verification of Virus Particle Production for a Personalized Vaccine
Nantbio, Inc.
0 cites